In initial phase 2a trials, only the therapeutic effects (i.e., improvement of hepatic steatosis and fibrosis) were evaluated with noninvasive liver tests, such as transient, shear wave, acoustic radiation, magnetic resonance elastography, and serum scores such as aspartate aminotransferase (AST) to alanine aminotransferase (ALT) ratios, AST to platelet ratio index (APRI), Fibrosis-4 (FIB-4), and NAFLD fibrosis scores. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.